HomeCompareZTOP vs ABBV

ZTOP vs ABBV: Dividend Comparison 2026

ZTOP yields 5.79% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $73.0K in total portfolio value
10 years
ZTOP
ZTOP
● Live price
5.79%
Share price
$51.41
Annual div
$2.98
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.3K
Annual income
$837.40
Full ZTOP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ZTOP vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZTOPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZTOP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZTOP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZTOP
Annual income on $10K today (after 15% tax)
$492.03/yr
After 10yr DRIP, annual income (after tax)
$711.79/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,344.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZTOP + ABBV for your $10,000?

ZTOP: 50%ABBV: 50%
100% ABBV50/50100% ZTOP
Portfolio after 10yr
$65.8K
Annual income
$12,804.58/yr
Blended yield
19.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ZTOP
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZTOP buys
0
ABBV buys
0
No recent congressional trades found for ZTOP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZTOPABBV
Forward yield5.79%3.06%
Annual dividend / share$2.98$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$29.3K$102.3K
Annual income after 10y$837.40$24,771.77
Total dividends collected$7.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZTOP vs ABBV ($10,000, DRIP)

YearZTOP PortfolioZTOP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,279$578.86$11,550$430.00$271.00ABBV
2$12,679$610.18$13,472$627.96$793.00ABBV
3$14,207$641.03$15,906$926.08$1.7KABBV
4$15,873$671.32$19,071$1,382.55$3.2KABBV
5$17,685$700.97$23,302$2,095.81$5.6KABBV
6$19,653$729.90$29,150$3,237.93$9.5KABBV
7$21,787$758.05$37,536$5,121.41$15.7KABBV
8$24,097$785.38$50,079$8,338.38$26.0KABBV
9$26,596$811.84$69,753$14,065.80$43.2KABBV
10$29,295$837.40$102,337$24,771.77$73.0KABBV

ZTOP vs ABBV: Complete Analysis 2026

ZTOPStock

The F/m High Yield 100 ETF is an actively managed exchange-traded fund that aims to provide investors with exposure to high-yield corporate bonds. The fund seeks to achieve its investment objective by investing in a diversified portfolio of 100 high-yield corporate bonds, focusing on maximizing income while managing credit risk.

Full ZTOP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ZTOP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZTOP vs SCHDZTOP vs JEPIZTOP vs OZTOP vs KOZTOP vs MAINZTOP vs JNJZTOP vs MRKZTOP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.